Cas:61825-94-3 Oxaliplatin manufacturer & supplier

Chemical Name:Oxaliplatin

CAS.NO:61825-94-3

Synonyms:Dacplat;Oxaliplatin;MFCD00866327;platinum, [ethanedioato(2-)-κO,κO]-, compd. with (1R,2R)-1,2-cyclohexanediamine (1:1);Platinum(2+) ethanedioate – (1R,2R)-1,2-cyclohexanediamine (1:1);Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1);[Ethanedioato(2-)-κO,O]platinum – (1R,2R)-cyclohexane-1,2-diamine (1:1);Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1);Elocatin

Molecular Formula:C₈H₁₂N₂O₄Pt

Molecular Weight:395.28

HS Code:28439000

Physical and Chemical Properties:

Melting point:N/A

Boiling point:193.6ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:104.64000

Exact Mass:

LogP:0.61450

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 2811 6.1/PG 2

Packing Group:II

Contact us for information like Dacplat chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Elocatin physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Elocatin Use and application,Platinum(2+) ethanedioate (1R,2R)-1,2-cyclohexanediamine (1:1:1) technical grade,usp/ep/jp grade.

Related News: The company memo said Lilly couldn’t substantiate allegations that employees faced retaliation for refusing to make false statements. It did not address employees’ specific complaints that they faced retaliation for other reasons, other than to say it encouraged employees to “speak up.” Oxaliplatin manufacturer In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum. Oxaliplatin supplier In order to seize the highest point of profits, international industry giants have adjusted their development strategies, concentrated their energies on the two ends of the smile curve-research and development and end products, and shifted production links such as intermediates and APIs outward. A division of labor model has been formed. Oxaliplatin vendor The company memo said Lilly couldn’t substantiate allegations that employees faced retaliation for refusing to make false statements. It did not address employees’ specific complaints that they faced retaliation for other reasons, other than to say it encouraged employees to “speak up.” Oxaliplatin factory In recent years, there has been a relatively concentrated concentration of intermediate companies listed on the capital market. Most of the fund-raising projects are aimed at breaking through the bottleneck of production capacity to meet growing demand, and the entire industry has shown a vigorous development momentum.